Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $90.00 short put and a strike $85.00 long put offers a potential 5.49% return on risk over the next 39 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $90.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock dropped below the $85.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 70.85 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
1 Year After the Spin-Off, Abbott Laboratories Looks Like a Winner
Tue, 14 Jan 2014 23:47:59 GMT
Motley Fool – Strong and steady demand in key products. recent acquisitions, and lower costs provide plenty of opportunity for Abbott Laboratories (ABT).
FDA Review Suggests Skepticism of Johnson & Johnson Drug’s Efficacy
Tue, 14 Jan 2014 21:35:05 GMT
Wall St. Cheat Sheet – An FDA review of Johnson & Johnson's Xarelto drug suggests the agency is highly skeptical of the company's proposed new application for the medicine.
TSG Shops Beauty Brands in Hot Sector
Tue, 14 Jan 2014 21:03:00 GMT
TheStreet – TSG Consumer Partners is still shopping its beauty brands, but has switched strategies and is trying to sell the brands separately instead of as one business, according to sources.
Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel
Tue, 14 Jan 2014 19:47:00 GMT
Forbes – The third time may not be the charm. Twice before the FDA has turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson's Xarelto (rivaroxaban). On Thursday the Cardiovascular and Renal Drugs Advisory Committee will take up the sNDA yet again, but FDA review […]
4 Free Cash Flow Kings That Really Look After Their Shareholders
Tue, 14 Jan 2014 19:19:50 GMT
Motley Fool – Philip Morris, Pfizer, McDonald's, and Johnson & Johnson have the best cash flows in their respective businesses.
Also on Market Tamer…
Follow Us on Facebook